drugset / Trial / NCT02060916

Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

NCT02060916 ↗

Phase 2 Completed 24 enrolled Boston Therapeutics
NaSingle-groupSingle-blindTreatment

Summary

This study is to evaluate the effect that PAZ320 has on post-prandial glucose excursions measured via continuous glucose monitoring and its adverse effect profile in humans.

Timeline

Start
2011-03
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PAZ320 Unknown — —